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Abstract
Background: In children with Henoch-Schonlein purpura nephritis (HSPN), the degree of proteinuria has been
proven to be not only a sign of kidney damage, but also an accelerator of kidney disease progression. Nephrotic
proteinuria at disease onset has been proposed as a predictor of a poor renal outcome. This study aims to assess
the clinical and pathological features of HSPN with nephrotic proteinuria in a single center.
Methods: One hundred thirty-seven patients with HSPN who visited Shanghai Children’s Hospital from January
2009 to December 2013 were retrospectively reviewed. The patients were divided into 2 groups based on the 24-h
urinary protein levels: nephrotic proteinuria group (NP group: 24-h urinary protein ≥50 mg/kg) and non-nephrotic
proteinuria group (NNP group: 24-h urinary protein <50 mg/kg). In addition, data regarding their sex, age, clinical
features, renal pathology, and prognosis were collected.
Results: (1) There were 34 boys and 20 girls in the NP group with a mean age of 8.39 ± 2.85 years. The peak age
of incidence was 6 to 11 years (72.22%). (2) There were 8 cases (14.81%) with joint symptoms and 9 cases (16.67%)
with gastrointestinal symptoms in the NP group. According to the analysis of the laboratory test results, the serum
albumin and IgG levels of the NP group were significantly lower than that of the NNP group (35.04 ± 8.45 in the NP
group vs. 41.55 ± 4.46 in the NNP group, P < 0.0001; 7.68 ± 3.12 in the NP group vs. 9.53 ± 2.74 in the NNP group,
P < 0.001, respectively); their blood urea nitrogen and cystatin C levels increased significantly (P < 0.05). (3) The
majority of the pathological changes in the NP group were above the International Study of Kidney Disease in
Children (ISKDC) grade III (62.97%). The NP group patients with tubulointerstitial injurie with grade 2 and above
(50%) were prioritized. Immune complex deposition in the NP group was dominated by IgA. (4) The prognosis of
the NP group was in complete remission (A), and their cases did not develop into end-stage renal disease; their
prognosis was also associated with clinical classification (P < 0.01) but was not related to pathologic grading and
tubulointerstitial injury (P > 0.05).
Conclusion: The serum albumin and IgG levels of the NP group were significantly lower; however, their blood urea
nitrogen and cystatin C levels were higher. The ISKDC grades were mainly above grade III. The prognosis of the NP
group was associated with clinical classification and improved after a timely and early treatment.
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Background
The long-term outcomes of Henoch-Schonlein purpura
(HSP), a common type of systemic vasculitis in children,
depend on its renal involvement [1]; such condition is
referred to as HSP nephritis (HSPN). A previous epi-
demiological survey showed that the incidence of HSPN
has gradually risen in recent years. Furthermore, the de-
gree of proteinuria has been proven to be not only a sign
of kidney damage but also an accelerator of kidney
disease progression [2]. Nephrotic proteinuria (NP) in
HSPN often yields a poor prognosis. Therefore, it is im-
portant to detect NP in HSPN cases. However, no previ-
ous studies have investigated the relationship between
the outcomes and clinical features of NP in HSPN. On
this basis, children with HSPN who presented with NP
were retrospectively studied to define the risk factors of
poor prognosis accurately and provide a foundation for
clinical treatment.
Methods
One hundred thirty-seven children diagnosed with HSPN
who were admitted to Shanghai Children’s Hospital
between January 2009 and December 2013 were retro-
spectively analyzed.
A retrospective analysis of all the data of the selected
patients was performed by reviewing their medical files.
The patients were divided into the NP group (24-h urin-
ary protein ≥50 mg/kg) and non-NP (NNP) group (24-h
urinary protein <50 mg/kg) based on their 24-h urinary
protein levels. General information, which included age,
sex, height, and weight, and symptoms, which included
the frequency of skin, joint, and gastrointestinal involve-
ments of the 137 patients were evaluated. The levels of
albumin (Alb), blood urea nitrogen (BUN), serum cre-
atinine (Scr), uric acid (UA), cystatin C (Cys-C), pro-
thrombin time (PT), activated partial prothrombin time
(APTT), thrombin time (TT), fibrinogen (FIB), fibrino-
gen degradation product (FDP), D-dimer, antithrombin
III (AT-III), platelet (PLT), estimated glomerular filtra-
tion rate (eGFR), immunoglobulins (IgA, IgG, IgM, and
IgE), cellular immunity, and complements were also
evaluated.
The clinical spectrum of HSPN ranges from isolated
microscopic hematuria to nephrotic syndrome, rapidly
progressive glomerulonephritis, and renal failure.
The histological grades of the renal biopsy were graded
in accordance with the International Study of Kidney
Disease in Children (ISKDC) classification [3] as follows:
grade I, minor glomerular abnormalities; grade II, pure
mesangial proliferation; grade III, minor glomerular ab-
normalities or mesangial proliferation, with crescents/
segmental lesions (sclerosis, adhesion, thrombosis, and
necrosis) in <50% of the glomeruli; grade IV, same as
grade III but with crescents/segmental lesions in 50–
75% of the glomeruli; grade V, same as grade III but with
crescents/segmental lesions in >75% of the glomeruli;
and grade VI, membranoproliferative-like lesions and
tubulointerstitial lesions (interstitial inflammation or fi-
brosis and tubular loss); the vascular component was
graded as follows: grade 1, essentially normal; grade 2,
<25%; grade 3, 25% to 50%; and grade 4, >50% [4].
Long-term outcomes were classified as follows [3]:
A, normal (no hypertension and normal physical
examination, urine, and renal function); B, minor
urinary abnormalities (normal physical examination
with microscopic hematuria or mild proteinuria); C,
active renal disease (Hypertension, heavy proteinuria,
or eGFR of <90 mL/min/1.73 m2); and D, end-stage
renal disease (ESRD) or death.
Statistical analyses
All statistical analyses were performed using the SAS
software. Quantitative variables were reported as mean
± standard deviation. In addition, the Spearman rank
correlation test was used in the analysis of the correla-
tions. P < 0.05 was considered statistically significant.
Results
Clinical features
This study included 137 patients, with 80 boys and 57
girls, making the boy to girl ratio 1.40:1. The NP group
had 54 patients (34 boys, 20 girls; boy:girl = 1.70:1), and
the NNP group had 83 patients (46 boys, 37 girls; boy:-
girl = 1.24:1) (Fig. 1). The statistical data showed that
there were significantly more boys than girls; however,
the NP group and NNP group exhibited no sex differ-
ences (P > 0.05) (Fig. 1).
The age of all patients ranged from 3 to 16 years, and
the mean age was 8.50 ± 2.91 years. The mean age of the
NP group was 8.39 ± 2.85 years, and the peak age was
6–11 years (72.22%), especially the range of 6–8 years
Fig. 1 Sex distribution of the NP and NNP groups. The NP group had
34 boys (42.50% of the total boys) and 20 girls (35.09% of the total
girls). The NNP group had 46 boys (57.50% of the total boys) and 37
girls (64.91% of the total girls). NP, nephrotic proteinuria; NNP, non-NP
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old. The mean age of the NNP group was 9.21 ±
2.94 years. These two sets of data exhibited no statisti-
cally significant differences (Fig. 2).
There was a clear specificity of HSPN with NP clin-
ical manifestations. There were 8 cases (14.81%) with
joint symptoms and 9 cases (16.67%) with gastrointes-
tinal symptoms in the NP group; there were 10 cases
(12.04%) with joint symptoms and 12 cases (14.46%)
with gastrointestinal symptoms in the NNP group.
Compared with the NNP group, the NP group had
more patients with joint and gastrointestinal symp-
toms. However, no statistically significant difference
was found by the comparison (P > 0.05). Data are
shown in Fig. 3.
Laboratory examination
To further investigate the characteristics and significance
of NP in HSPN, the laboratory test results of all patients
with HSPN were analyzed. The NP group had lower
blood Alb and higher BUN and Cys-C levels (P < 0.05).
The results are shown in Table 1.
Immunologic analysis
At the beginning of the process of the illness, there were
obvious abnormalities in the humoral and cellular im-
munities in the children diagnosed with HSPN. Im-
munological index included blood immunoglobulin
levels (IgA, IgG, IgM, and IgE) and lymphocyte sub-
group analysis (CD3+, CD4+, CD8+, CD16 + 56+/CD3+,
CD19+, and CD4+/CD8+). Further, the level of comple-
ments (CH50, C3, and C4) was analyzed. The statistical
analysis showed that the level of blood IgG of the NP
group was lower than that of the NNP group (P < 0.05).
The results are shown in Table 2.
Pathological features
ISKDC grading score
The results of the ISKDC grading score at onset showed
that 35 patients had grade I, 36 had grade II, 48 had
grade IIIa, 11 had grade IIIB, and 6 had above grade IV.
Grade IIIa was the most common. Among the NP group
patients, 5 patients (9.26%) had grade I, 15 (27.78%) had
grade II, 34 (62.97%) had above grade III. Different from
the NP group patients, most NNP group patients had
grade I (37.35%), followed by grade IIIa (32.53%). The
results showed a significant difference between the two
groups (Table 3) and indicated that the renal patho-
logical tissue damage in the NP group was significantly
greater than that in the NNP group.
Immune complex deposition
Through the kidney mesangial area immunofluorescence
sedimentation analysis, 17 cases in the NP group had
IgA deposits, 15 had IgA + IgM deposits, and 14 had
IgA + IgM + IgG deposits. Most patients had IgA de-
posits, followed by IgA + IgM deposits. In the NNP
group, most patients also had IgA deposits but followed
by IgA + IgM + IgG deposits. There was no statistical
difference between the two groups in terms of immune
complex deposition type (P > 0.05). The results are
shown in Table 4.
In the study, 63.50% of the children had immune
deposits associated with C3 deposition; the rest of the
patients did not have C3 deposits. There was no statis-
tical significance between C3 deposition and urine
protein quantitative results (P > 0.05) (Table 5).
Tubulointerstitial injuries
Of the 137 patients, 91 patients (66.42%) had grade 1,
37 (27.01%) had grade 2, 8 (5.84%) had grade 3, and
1 (0.73%) had grade 4 tubulointerstitial injuries. In
both groups, most patients had grade 1, followed by
grade 2 injuries. The difference in tubulointerstitial
injuries between the two groups had a statistical
significance (P < 0.01). The results showed that the
Fig. 2 Age distribution of the NP and NNP groups. The youngest
patient was 3 years old, and the oldest patient was 16 years old. We
divided the patients into 4 groups according to their age. NP,
nephrotic proteinuria; NNP, non-NP
Fig. 3 The clinical features of the NP and NNP groups. the NP group had
more patients with joint (14.81%) and gastrointestinal (16.67%) symptoms
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tubulointerstitial injuries of the NP group were more
serious than that of the NNP group. The results are
shown in Table 6.
Nephrotic-range proteinuria in HSPN prognostic analysis
In our study, all patients had a follow-up of 6 months to
5 years, and the mean follow-up was 43.10 ± 16.39 months.
Among them, 68.52% had a good outcome (A), 27.78%
had mild urinary anomalies (B), only 2 had a remained
active renal disease (C), and no patient had an ESRD pro-
gression (D).
Correlation analysis of the clinical classification and
prognosis
The clinical classification of the NP group mainly in-
volved hematuria and proteinuria, since there was no
case of isolated proteinuria or isolated hematuria. There
were 37 patients (68.52%) with a complete remission
(A), and only 2 patients (3.7%) had an active renal dis-
ease (C). There were clinical manifestations in 6 patients
with nephrotic syndrome (11.11%) and mild urinary
anomalies (B). One case of radical nephritis developed
into minor urinary abnormalities (B). One case of rapidly
Table 1 Comparison of laboratory data at one set in NP and NNP
Laboratory data NP group x− ±s NNP group x− ±s t-test/Wilcoxon P
PLT 342.02 (91.55) 317.98 (97.18) −1.57 0.12
AT-3 165.8 (50.18) 178.2 (52.51) 1.36 0.18
PT 11.14 (0.86) 11.29 (0.90) 1.01 0.31
APTT 25.65 (4.41) 26.69 (4.61) 1.38 0.17
FIB 2.76 (0.92) 2.58 (0.74) −1.35 0.18
FDP 1.60 (2.60) 2.20 (4.70) −1.74 0.08
D-dimer 0.30 (0.60) 0.20 (0.35) 1.59 0.11
eGFR 175.10 (58.31) 184.30 (41.36) 1.07 0.29
Alb 35.04 (8.45) 41.55 (4.46) 5.47 <0.0001
BUN 5.81 (3.32) 4.72 (3.25) −2.03 0.04
Cr 43.82 (24.83) 40.11 (16.59) −1.03 0.31
UA 308.30 (91.86) 275.10 (78.93) −1.68 0.09
Cys-c 1.19 (0.57) 0.85 (0.26) −2.76 0.01
Table 2 Comparison of immune function in NP and NNP
NP group x− ±s (n = 54) NNP group x− ±s (n = 83) t-test/Wilcoxon P
Lymphocyte subgroup
CD3+ 58.38 (21.33) 59.99 (19.09) 0.48 0.63
CD4+ 26.42 (11.44) 27.59 (10.12) 0.65 0.52
CD8+ 26.04 (10.61) 26.38 (9.51) 0.20 0.84
CD16 + 56+/CD3+ 10.43 (7.24) 12.94 (7.64) 1.96 0.051
CD19+ 18.46 (9.36) 17.78 (8.59) −0.45 0.66
CD4+/CD8+ 1.01 (0.56) 1.01 (0.48) −0.33 0.74
Immunoglobulin
IgG 7.68 (3.12) 9.53 (2.74) 3.85 0.0002
IgA 2.17 (0.73) 2.33 (0.73) 1.37 0.17
IgM 1.23 (0.49) 1.25 (0.52) 0.32 0.75
IgE 68.15 (136.10) 89.60 (191.20) −0.92 0.36
Complement
CH50 50.86 (10.84) 50.47 (11.98) −0.20 0.85
C3 1.15 (0.22) 1.21 (0.22) 1.45 0.15
C4 0.23 (0.08) 0.22 (0.08) −0.95 0.34
Feng et al. Pediatric Rheumatology  (2017) 15:15 Page 4 of 8
progressive glomerulonephritis developed into active
renal disease (C). As shown in Table 7, the different clin-
ical classifications of the prognostic difference in the NP
group had a statistical significance (P < 0.01). The more
severe the clinical manifestations were, the worse the
prognosis was.
Pathological grading and prognosis analysis
In the NP group, all patients with grade I had a
complete remission (A), 8 (14.81%) with grade II showed
a complete remission (A), 6 (11.11%) had mild urinary
anomalies (B), and only 1 (1.85%) showed an active renal
disease (C). Twenty-five patients (46.29%) with grades
III–VI had good outcomes (A), 8 (14.82%) had mild
urinary anomalies, and only 1 (1.85%) showed an active
renal disease (C). No correlation existed between the
pathological grading and prognosis (Table 8).
Tubulointerstitial injuries and prognosis analysis
Of 54 patients, 66.67% with grade 1 had a complete re-
mission (A), 8 (29.62%) had a poor prognosis for mild
urinary anomalies (B), 13 (65.00%) with grade 2 showed
a complete remission (A), and 7 (35.00%) had a poor
prognosis for mild urinary anomalies (B). Six patients
(85.17%) with grades III–IV had good outcomes (A).
Only 1 patient (1.85%) showed an active renal disease
(C). No correlation existed between the tubulointerstitial
injuries and prognosis (P > 0.05). The results are shown
in Table 9.
Treatment and prognosis analysis
The therapies of HSPN include steroids, immunosup-
pressive agents, angiotensin converting enzyme inhibi-
tors (ACE-I) and/or angiotensin receptor blockers
(ARB), plasmapheresis, and tonsillectomy. At our insti-
tutes, all treatment decisions are based on the clinical
and pathological severities of the patient conditions.
In our study, the main treatment in the NP group was
steroids combined with mycophenolate mofetil (46.30%).
The secondary treatment was methylprednisolone pulse
therapy (20–30 mg/kg/d, maximal dose 1 g) for 3 days;
steroids combined with mycophenolate mofetil (25.93%)
were used thereafter. Thirty-eight patients (70.37%) had
a complete remission (A). Only 2 patients (3.70%)
showed an active renal disease (C). The results showed
that the prognosis of the NP group improved after a
timely and early treatment. Further, these therapies had
no obvious adverse effects (Table 10).
Discussion
HSPN is a renal disease secondary to HSP; when this oc-
curs, secondary glomerulonephritis, morbidity after neph-
rotic syndrome, and acute glomerulonephritis commonly
develop. An accumulating evidence indicates that protein
in the urine is not only a sign of kidney damage but also a
crucial indicator for kidney disease progression and a crit-
ical prognosis factor [2]. For instance, nephrotic-range
proteinuria of HSPN often prompts a poor outcome.
Our study showed that there were significantly more
boys than girls, with a ratio of 1.40:1. In the NP group, the
ratio was 1.70:1, which is consistent with those of previous
reports in the literature [5]. Some studies reported that
Table 3 Comparison of biopsy findings in NP and NNP
ISKDC grading
score
NP group n (%)
(n = 54)
NNP group n (%)
(n = 83)
Total n (%)
I 5 (9.26) 31 (37.35) 36 (26.28)
II 15 (27.78) 21 (25.30) 36 (26.28)
IIIa 21 (38.89) 27 (32.53) 48 (35.04)
IIIb 8 (14.81) 3 (3.61) 11 (8.03)
IV a 3 (5.56) 1 (1.20) 4 (2.92)
IV b 0 (0.00) 0 (0.00) 0 (0.00)
Va 0 (0.00) 0 (0.00) 0 (0.00)
Vb 1 (1.85) 0 (0.00) 1 (0.73)
VI 1 (1.85) 0 (0.00) 1 (0.73)
X2 = 20.58, P < 0.01




NP group n (%)
(n = 54)
NNP group n (%)
(n = 83)
Total n (%)
IgA 17 (31.48) 26 (31.33) 43 (31.39)
IgA + IgG 8 (14.81) 18 (21.69) 26 (18.98)
IgA + IgM 15 (27.78) 19 (22.89) 34 (24.82)
IgA + IgG + IgM 14 (25.93) 20 (24.10) 34 (24.82)
X2 = 1.17,P > 0.05
Table 5 Comparison of C3 immunofluorescence findings in NP
and NNP
NP group n (%) NNP group n (%) Total n (%)
C3 deposits 35 (25.55) 52 (37.96) 72 (63.50)
no C3 deposits 19 (13.87) 31 (22.63) 39 (36.50)
X2 = 0.0661,P > 0.05
Table 6 Comparison of tubulointerstitial findings in NP and NNP
Tubulointerstitial
injury grading
NP group n (%) NNP group n (%) Total n (%)
grade 1 27 (19.71) 64 (46.72) 91 (66.42)
grade 2 21 (15.33) 16 (11.68) 37 (27.01)
grade 3 5 (3.65) 3 (2.19) 8 (5.84)
grade 4 1 (0.73) 0 (0.00) 1 (0.73)
Total 54 (42.03) 83 (57.97) 137 (100.00)
X2 = 11.6008, P < 0.01
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the risk of HSPN increases with age; in particular, cases of
children over 10 years of age were more likely to progress
to HSPN [6–8]. The age of the NP group in the present
study ranged from 4 to 16 years, and the mean age of
onset was 8.39 ± 2.85 years. In the NNP group, the age of
onset was 9.21 ± 2.94 years. These results suggest that
there exists no significant difference between the 2 groups,
which is in contrast to the findings published by a number
of other previous studies.
In the analysis of the laboratory test results, the NP
group exhibited a significantly lower level of serum Alb
and IgG; however, the level of BUN and Cys-C increased
significantly. There were few studies on humoral and
cellular immunities with various degrees of proteinuria
in HSPN [9–11]. We found that the NP group exhibited
a significantly lower level of IgG, which agrees with the
results of previous reports in the literature [10]. Two
viewpoints may explain why the NP group had a lower
level of IgG; first, the glomerular filtration membrane
electrostatic barrier and/or capillary wall barrier function
were impaired, resulting in a large number of IgG lost
from the urine; second, it may be related to the abnor-
mal functioning of lymphocytes T and B. The results
show that these factors can be used as sensitive
biological indicators of the severity of HSPN, which can
provide an early and reliable information for its progno-
sis and treatment.
Nickavar et al. [12] suggested that NP in HSPN had
higher pathological grades. Chen et al. [13] in addition
to reporting a similar finding also suggested that renal
tubulointerstitial lesions positively correlated with the
disease. In the present study, the majority of the patho-
logical changes in the NP group involved grade III
(53.70%), followed by grade II (27.78%). Consequently,
our findings are consistent with those of Chen et al.
[13]. The results of the present study suggested that the
renal pathological damage in the NP group was signifi-
cantly greater than that in the NNP group (P < 0.05).
There is growing concern on renal tubulointerstitial le-
sions both in China and abroad; however, there is still a
lack of large-scale studies. Our study showed that the
tubulointerstitial injuries in the NP group were more
serious than those in the NNP group, which is in con-
trast to the findings of a previous study [13].
The main characteristics of the immune complex de-
position in HSPN primarily involved IgA deposition,
followed by IgG or IgM deposits, and complement com-
ponents C3, followed by C4 and C1q deposits. Further,
the capillary walls have varying degrees of involvement
[14]. The present study showed immune complex depo-
sitions in NP group (mainly IgA immune deposits,
followed by IgA + IgM immune deposits). In the study,
63.5% patients had C3 deposition; the results suggested
that the complement immune process was involved in
HSPN; however, C3 deposition was not correlated with
urinary function (P > 0.05).
Several authors have discussed that the prognosis of
the patients with HSPN is closely related to its clinical
manifestation. In the clinical evaluation of hematuria
and/or microscale protein in the urine of children, 5% of
the cases developed into chronic kidney failure; 40% of
the nephritic syndrome cases progressed to chronic
kidney failure. Over 50% of cases that showed both
nephrotic syndrome and nephritic syndrome developed
into chronic kidney failure. Moreover, even subtle abnor-
malities in the urine may develop into chronic kidney
failure after 10 years [15]. This study shows that patients
with hematuria and urinary protein had a good outcome
Table 7 Outcome in relation clinical features at onset
Clinical manifestations A n (%) B n (%) C n (%) D n (%)
isolated hematuria 0 (0.00) 0 (0.00) 0 (0.00) 0 (0.00)
isolated proteinuria 0 (0.00) 0 (0.00) 0 (0.00) 0 (0.00)
Hematuria and proteinuria 30 (55.56) 8 (14.81) 1 (1.85) 0 (0.00)
radical nephritis 0 (0.00) 1 (1.85) 0 (0.00) 0 (0.00)
Nephrotic syndrome 7 (12.96) 6 (11.11) 0 (0.00) 0 (0.00)
Rapidly progressive
glomerulonephritis
0 (0.00) 0 (0.00) 1 (1.85) 0 (0.00)
Total 37 (68.52) 15 (27.78) 2 (3.7) 0 (0.00)
X2 = 32.3501; P < 0.0001
Table 8 Outcome in relation to biopsy findings
Pathological grading A n (%) B n (%) C n (%) D n (%)
I 4 (7.41) 1 (1.85) 0 (0.00) 0 (0.00)
II 8 (14.81) 6 (11.11) 1 (1.85) 0 (0.00)
IIIa 16 (29.63) 4 (7.41) 1 (1.85) 0 (0.00)
IIIb 4 (7.41) 4 (7.41) 0 (0.00) 0 (0.00)
IV 3 (5.56) 0 (0.00) 0 (0.00) 0 (0.00)
V 1 (1.85) 0 (0.00) 0 (0.00) 0 (0.00)
VI 1 (1.85) 0 (0.00) 0 (0.00) 0 (0.00)
合计 37 (68.52) 15 (27.78) 2 (3.70) 0 (0.00)
X2 = 7.2936; P = 0.8376
Table 9 Outcome in relation to tubulointerstitial findings
Tubulointerstitial injury grading A n (%) B n (%) C n (%) D n (%)
grade 1 18 (33.33) 8 (14.81) 1 (1.85) 0 (0.00)
grade 2 13 (24.07) 7 (12.96) 0 (0.00) 0 (0.00)
grade 3 5 (9.26) 0 (0.00) 1 (1.85) 0 (0.00)
grade 4 1 (1.85) 0 (0.00) 0 (0.00) 0 (0.00)
Total 37 (68.52) 15 (27.78) 2 (3.70) 0 (0.00)
X2 = 7.228; P = 0.352
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(A) 46.15% of the patients with nephrotic syndrome had
mild urinary anomalies and (B) all patients with radical
nephritis also had mild urinary anomalies. The descrip-
tion of patients with nephrotic-range proteinuria of
HSPN prognosis was closely related to its clinical classi-
fication; however, this requires a long-term follow-up
study in the future.
We also did not find any difference between the patho-
logical and tubulointerstitial injuries in relation to the
outcome, which is in contrast to the findings published by
Halling et al. [16], who found that ISKDC grades III–V
have a worse outcome than grades I–II. There may be a
relationship between small-scale data samples and a rea-
sonable treatment used in a timely manner.
In our study, the choice of treatment for HSPN
depended on both the histological and clinical severity of
the patient conditions [13, 14, 17]. All patients received
ACE-I and/or ARB, and dipyridamole. In the NP group,
72.23% of the patients were treated with steroids and my-
cophenolate mofetil. After the follow-up of 6 months to
5 years, 38 patients (70.37%) had a complete remission
(A), only 2 showed an active renal disease (C), and no
cases progressed to ESRD. Our data indicate that a
combination therapy, such as steroids with mycopheno-
late mofetil, is effective for histologically or clinically
severe HSPN. However, tripterygium glycosides may
affect the reproductive system; this side effect limited
its clinical application. In our study, the follow-up
period was <5 years; the presence of a poor prognosis
may exist over a long period.
Conclusion
NP in HSPN is a serious condition. The NP group
had a significantly lower level of serum Alb and IgG
but a significantly increased level of BUN and Cys-C.
The biopsy findings were mainly above grade III. The
prognosis of the NP group was associated with the
clinical classification and improved after a timely and
early treatment.
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Table 10 Outcome in relation treatment of NP group
Treatment A n (%) B n (%) C n (%) D n (%) Total n (%)
steroids 2 (3.70) 1 (1.85) 0 (0.00) 0 (0.00) 3 (5.56)
steroids and GTW 4 (7.41) 1 (1.85) 0 (0.00) 0 (0.00) 5 (9.26)
steroids and MMF 27 (50.00) 10 (18.52) 2 (3.70) 0 (0.00) 39 (72.23)
steroids and CTX 2 (3.70) 2 (3.70) 0 (0.00) 0 (0.00) 4 (7.41)
steroids and CsA 1 (1.85) 0 (0.00) 0 (0.00) 0 (0.00) 1 (1.85)
steroids and FK506 2 (3.70) 0 (0.00) 0 (0.00) 0 (0.00) 2 (3.70)
Total 38 (70.37) 14 (25.93) 2 (3.70) 0 (0.00) 54 (100.00)
X2 = 3.26; P > 0.05
GTW tripterygium glycosides, MMF mycophenolate mofetil, CTX cyclophosphamide, CsA cyclosporine A, FK506 tacrolimus
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